Trial Profile
A Study Investigating Daratumumab-Based Combination Therapies in Heavily-Pretreated Patients with Relapsed and/or Refractory Multiple Myeloma
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 22 Jul 2017
Price :
$35
*
At a glance
- Drugs Daratumumab (Primary)
- Indications Multiple myeloma
- Focus Therapeutic Use
- 22 Jul 2017 New trial record
- 25 Jun 2017 Results presented at the 22nd Congress of the European Haematology Association.